NPJ Schizophrenia最新文献

{"title":"Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study.","authors":"Sanne Hoekstra,&nbsp;Christoffer Bartz-Johannessen,&nbsp;Igne Sinkeviciute,&nbsp;Solveig K Reitan,&nbsp;Rune A Kroken,&nbsp;Else-Marie Løberg,&nbsp;Tor K Larsen,&nbsp;Maria Rettenbacher,&nbsp;Erik Johnsen,&nbsp;Iris E Sommer","doi":"10.1038/s41537-021-00170-3","DOIUrl":"https://doi.org/10.1038/s41537-021-00170-3","url":null,"abstract":"<p><p>Current guidelines for patients with schizophrenia spectrum disease do not take sex differences into account, which may result in inappropriate sex-specific treatment. In the BeSt InTro study, a total of 144 patients (93 men and 51 women) with a schizophrenia spectrum diagnosis and ongoing psychosis were included and randomized to amisulpride, aripiprazole, or olanzapine in flexible dose. This trial is registered with ClinicalTrials.gov (NCT01446328). Primary outcomes were sex differences in dose, dose-corrected serum levels, efficacy, and tolerability. Dosing was higher for men than for women in the aripiprazole group (p = 0.025) and, at trend level, in the olanzapine group (p = 0.056). Dose-corrected serum levels were 71.9% higher in women than in men for amisulpride (p = 0.019) and 55.8% higher in women than in men for aripiprazole (p = 0.049). In the amisulpride group, men had a faster decrease in psychotic symptoms than women (p = 0.003). Moreover, amisulpride was more effective than the other medications in men but not in women. Prolactin levels were higher in women than in men, especially for amisulpride (p < 0.001). Also, women had higher BMI increase on amisulpride compared to the two other antipsychotics (p < 0.001). We conclude that clinicians should be aware of the risks of overdosing in women, especially for amisulpride and aripiprazole. Amisulpride is highly effective in men, but in women, amisulpride showed more severe side effects and may thus not be the drug of first choice. Our study shows that sex differences should be taken into account in future studies on antipsychotics. Future research is warranted to evaluate these preliminary results.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00170-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39323382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired cerebro-cerebellar white matter connectivity and its associations with cognitive function in patients with schizophrenia.","authors":"Sung Eun Kim,&nbsp;Sungcheol Jung,&nbsp;Gyhye Sung,&nbsp;Minji Bang,&nbsp;Sang-Hyuk Lee","doi":"10.1038/s41537-021-00169-w","DOIUrl":"https://doi.org/10.1038/s41537-021-00169-w","url":null,"abstract":"<p><p>Schizophrenia is a complex brain disorder of unknown etiology. Based on the notion of \"cognitive dysmetria,\" we aimed to investigate aberrations in structural white matter (WM) connectivity that links the cerebellum to cognitive dysfunction in patients with schizophrenia. A total of 112 participants (65 patients with schizophrenia and 47 healthy controls [HCs]) were enrolled and underwent diffusion tensor imaging. Between-group voxel-wise comparisons of cerebellar WM regions (superior/middle [MCP]/inferior cerebellar peduncle and pontine crossing fibers) were performed using Tract-Based Spatial Statistics. Cognitive function was assessed using the Trail Making Test Part A/B (TMT-A/B), Wisconsin Card Sorting Test (WCST), and Rey-Kim Memory Test in 46 participants with schizophrenia. WM connectivity, measured as fractional anisotropy (FA), was significantly lower in the MCP in participants with schizophrenia than in HCs. The mean FAs extracted from the significant MCP cluster were inversely correlated with poorer cognitive performance, particularly longer time to complete the TMB-B (r = 0.559, p < 0.001) and more total errors in the WCST (r = 0.442, p = 0.003). Our findings suggest that aberrant cerebro-cerebellar communication due to disrupted WM connectivity may contribute to cognitive impairments, a core characteristic of schizophrenia. Our results may expand our understanding of the neurobiology of schizophrenia based on the cerebro-cerebellar interconnectivity of the brain.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00169-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39307596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fingertip advanced glycation end products and psychotic symptoms among adolescents.","authors":"Mitsuhiro Miyashita,&nbsp;Syudo Yamasaki,&nbsp;Shuntaro Ando,&nbsp;Kazuhiro Suzuki,&nbsp;Kazuya Toriumi,&nbsp;Yasue Horiuchi,&nbsp;Akane Yoshikawa,&nbsp;Atsushi Imai,&nbsp;Yukihiro Nagase,&nbsp;Yasuhiro Miyano,&nbsp;Tomoko Inoue,&nbsp;Kaori Endo,&nbsp;Yuko Morimoto,&nbsp;Masaya Morita,&nbsp;Tomoki Kiyono,&nbsp;Satoshi Usami,&nbsp;Yuji Okazaki,&nbsp;Toshiaki A Furukawa,&nbsp;Mariko Hiraiwa-Hasegawa,&nbsp;Masanari Itokawa,&nbsp;Kiyoto Kasai,&nbsp;Atsushi Nishida,&nbsp;Makoto Arai","doi":"10.1038/s41537-021-00167-y","DOIUrl":"https://doi.org/10.1038/s41537-021-00167-y","url":null,"abstract":"<p><p>Case control studies have suggested that advanced glycation end products play a key role in the pathophysiology of chronic schizophrenia. However, the longitudinal association between advanced glycation end products and psychotic symptoms among drug-naïve adolescents remains unclear. This study examined whether advanced glycation end products could predict the trajectory of psychotic symptoms in drug-naive adolescents using data from prospective population-based biomarker subsample study of the Tokyo Teen Cohort. A total of 277 community-dwelling adolescents aged 13 years without antipsychotic medication were analyzed. Fingertip advanced glycation end products were measured in adolescents using noninvasive technology that can be used quickly. The trajectory of psychotic symptoms in a 12-month follow-up was assessed by experienced psychiatrists using a semi-structured interview. Of the 277 participants, 13 (4.7%) experienced persistent psychotic symptoms (psychotic symptoms at baseline and follow-up), 65 (23.5%) experienced transient psychotic symptoms (psychotic symptoms at baseline or follow-up), and 199 (71.8%) did not have psychotic symptoms. Multinomial logistic regression analysis adjusted for age and sex revealed that baseline fingertip advanced glycation end products might predict the risk of persistent psychotic symptoms (odds ratio = 1.68; 95% confidence interval, 1.05-2.69; P = 0.03). Altogether, fingertip advanced glycation end products potentially predicted the trajectory of psychotic symptoms among drug-naive adolescents, which indicated its involvement in the pathophysiology of early psychosis. Further studies are required to identify strategies to reduce adolescent advanced glycation end products, which may contribute to preventing the onset of psychosis.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00167-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39305899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic face processing impairments are associated with cognitive and positive psychotic symptoms across psychiatric disorders.","authors":"Hayley Darke,&nbsp;Suresh Sundram,&nbsp;Simon J Cropper,&nbsp;Olivia Carter","doi":"10.1038/s41537-021-00166-z","DOIUrl":"https://doi.org/10.1038/s41537-021-00166-z","url":null,"abstract":"<p><p>Impairments in social cognition-including recognition of facial expressions-are increasingly recognised as a core deficit in schizophrenia. It remains unclear whether other aspects of face processing (such as identity recognition) are also impaired, and whether such deficits can be attributed to more general cognitive difficulties. Moreover, while the majority of past studies have used picture-based tasks to assess face recognition, literature suggests that video-based tasks elicit different neural activations and have greater ecological validity. This study aimed to characterise face processing using video-based stimuli in psychiatric inpatients with and without psychosis. Symptom correlates of face processing impairments were also examined. Eighty-six psychiatric inpatients and twenty healthy controls completed a series of tasks using video-based stimuli. These included two emotion recognition tasks, two non-emotional facial identity recognition tasks, and a non-face control task. Symptoms were assessed using the Positive and Negative Syndrome Scale. Schizophrenia and bipolar disorder groups were significantly impaired on the emotion-processing tasks and the non-face task compared to healthy controls and patients without psychosis. Patients with other forms of psychosis performed intermediately. Groups did not differ in non-emotional face processing. Positive symptoms of psychosis correlated directly with both emotion-processing performance and non-face discrimination across patients. We found that identity processing performance was inversely associated with cognition-related symptoms only. Findings suggest that deficits in emotion-processing reflect symptom pathology independent of diagnosis. Emotion-processing deficits in schizophrenia may be better accounted for by task-relevant factors-such as attention-that are not specific to emotion processing.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00166-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10703279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurodevelopment regulators miR-137 and miR-34 family as biomarkers for early and adult onset schizophrenia.","authors":"Bao-Yu Chen,&nbsp;Jin-Jia Lin,&nbsp;Ming-Kun Lu,&nbsp;Hung-Pin Tan,&nbsp;Fong-Lin Jang,&nbsp;Sheng-Hsiang Lin","doi":"10.1038/s41537-021-00164-1","DOIUrl":"https://doi.org/10.1038/s41537-021-00164-1","url":null,"abstract":"<p><p>Early-onset schizophrenia (EOS) may have stronger familial aggregation and a more severe outcome than adult-onset schizophrenia (AOS). MicroRNA (miRNA) takes on dual roles as a genetic and epigenetic modulator, which may mediate the influence of genetic risk. Neurological soft signs (NSS) are neurological abnormalities that may be intermediate phenotypes or endophenotypes for schizophrenia. Our previous study found poorer performance on NSS tests from patients with EOS and their unaffected first-degree relatives. Thus, we aimed to identify a set of aberrant neurodevelopmental-related miRNAs that could serve as potential biomarkers for EOS or schizophrenia with NSS. This study included 215 schizophrenia patients (104 EOS and 111 AOS), 72 unaffected first-degree relatives, 31 patients with bipolar disorder, and 100 healthy controls. Differential expression analysis revealed that miR-137, miR-34b, and miR-34c were significantly up-regulated in patients with schizophrenia and their unaffected first-degree relatives compared to healthy controls. Receiver operating characteristic (ROC) analysis showed that the miR-137 expression signature could be used to discriminate between patients with EOS and healthy controls (AUC = 0.911). Additionally, miR-34b had the highest ability to discriminate between EOS and AOS (AUC = 0.810), which may indicate different aetiological pathways to disease onset. Moreover, miR-137 dysregulation was correlated with almost all NSS subscales (i.e., sensory integration, motor sequencing, etc.) and, when EOS patients with NSS, miR-137 expression discriminated these patients from healthy controls to a greater extent (AUC = 0.957). These findings support the potential for neurodevelopmental-related miRNAs to be used as indicators of vulnerability to EOS.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00164-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39153630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized prediction of three- and six-year outcomes of psychosis in a longitudinal multicenter study: a machine learning approach.","authors":"Jessica de Nijs,&nbsp;Thijs J Burger,&nbsp;Ronald J Janssen,&nbsp;Seyed Mostafa Kia,&nbsp;Daniël P J van Opstal,&nbsp;Mariken B de Koning,&nbsp;Lieuwe de Haan,&nbsp;Wiepke Cahn,&nbsp;Hugo G Schnack","doi":"10.1038/s41537-021-00162-3","DOIUrl":"https://doi.org/10.1038/s41537-021-00162-3","url":null,"abstract":"<p><p>Schizophrenia and related disorders have heterogeneous outcomes. Individualized prediction of long-term outcomes may be helpful in improving treatment decisions. Utilizing extensive baseline data of 523 patients with a psychotic disorder and variable illness duration, we predicted symptomatic and global outcomes at 3-year and 6-year follow-ups. We classified outcomes as (1) symptomatic: in remission or not in remission, and (2) global outcome, using the Global Assessment of Functioning (GAF) scale, divided into good (GAF ≥ 65) and poor (GAF < 65). Aiming for a robust and interpretable prediction model, we employed a linear support vector machine and recursive feature elimination within a nested cross-validation design to obtain a lean set of predictors. Generalization to out-of-study samples was estimated using leave-one-site-out cross-validation. Prediction accuracies were above chance and ranged from 62.2% to 64.7% (symptomatic outcome), and 63.5-67.6% (global outcome). Leave-one-site-out cross-validation demonstrated the robustness of our models, with a minor drop in predictive accuracies of 2.3% on average. Important predictors included GAF scores, psychotic symptoms, quality of life, antipsychotics use, psychosocial needs, and depressive symptoms. These robust, albeit modestly accurate, long-term prognostic predictions based on lean predictor sets indicate the potential of machine learning models complementing clinical judgment and decision-making. Future model development may benefit from studies scoping patient's and clinicians' needs in prognostication.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00162-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10701150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction of schizophrenia and chronic cannabis use on reward anticipation sensitivity.","authors":"Simon Fish,&nbsp;Foteini Christidi,&nbsp;Efstratios Karavasilis,&nbsp;Georgios Velonakis,&nbsp;Nikolaos Kelekis,&nbsp;Christoph Klein,&nbsp;Nicholas C Stefanis,&nbsp;Nikolaos Smyrnis","doi":"10.1038/s41537-021-00163-2","DOIUrl":"https://doi.org/10.1038/s41537-021-00163-2","url":null,"abstract":"<p><p>Chronic cannabis use and schizophrenia are both thought to affect reward processing. While behavioural and neural effects on reward processing have been investigated in both conditions, their interaction has not been studied, although chronic cannabis use is common among these patients. In the present study eighty-nine participants divided into four groups (control chronic cannabis users and non-users; schizophrenia patient cannabis users and non-users) performed a two-choice decision task, preceded by monetary cues (high/low reward/punishment or neutral), while being scanned using functional magnetic resonance imaging. Reward and punishment anticipation resulted in activation of regions of interest including the thalamus, striatum, amygdala and insula. Chronic cannabis use and schizophrenia had opposing effects on reward anticipation sensitivity. More specifically control users and patient non-users showed faster behavioural responses and increased activity in anterior/posterior insula for high magnitude cues compared to control non-users and patient users. The same interaction pattern was observed in the activation of the right thalamus for reward versus punishment cues. This study provided evidence for interaction of chronic cannabis use and schizophrenia on reward processing and highlights the need for future research addressing the significance of this interaction for the pathophysiology of these conditions and its clinical consequences.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00163-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39237631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The progression of disorder-specific brain pattern expression in schizophrenia over 9 years.","authors":"Johannes Lieslehto,&nbsp;Erika Jääskeläinen,&nbsp;Vesa Kiviniemi,&nbsp;Marianne Haapea,&nbsp;Peter B Jones,&nbsp;Graham K Murray,&nbsp;Juha Veijola,&nbsp;Udo Dannlowski,&nbsp;Dominik Grotegerd,&nbsp;Susanne Meinert,&nbsp;Tim Hahn,&nbsp;Anne Ruef,&nbsp;Matti Isohanni,&nbsp;Peter Falkai,&nbsp;Jouko Miettunen,&nbsp;Dominic B Dwyer,&nbsp;Nikolaos Koutsouleris","doi":"10.1038/s41537-021-00157-0","DOIUrl":"https://doi.org/10.1038/s41537-021-00157-0","url":null,"abstract":"<p><p>Age plays a crucial role in the performance of schizophrenia vs. controls (SZ-HC) neuroimaging-based machine learning (ML) models as the accuracy of identifying first-episode psychosis from controls is poor compared to chronic patients. Resolving whether this finding reflects longitudinal progression in a disorder-specific brain pattern or a systematic but non-disorder-specific deviation from a normal brain aging (BA) trajectory in schizophrenia would help the clinical translation of diagnostic ML models. We trained two ML models on structural MRI data: an SZ-HC model based on 70 schizophrenia patients and 74 controls and a BA model (based on 561 healthy individuals, age range = 66 years). We then investigated the two models' predictions in the naturalistic longitudinal Northern Finland Birth Cohort 1966 (NFBC1966) following 29 schizophrenia and 61 controls for nine years. The SZ-HC model's schizophrenia-specificity was further assessed by utilizing independent validation (62 schizophrenia, 95 controls) and depression samples (203 depression, 203 controls). We found better performance at the NFBC1966 follow-up (sensitivity = 75.9%, specificity = 83.6%) compared to the baseline (sensitivity = 58.6%, specificity = 86.9%). This finding resulted from progression in disorder-specific pattern expression in schizophrenia and was not explained by concomitant acceleration of brain aging. The disorder-specific pattern's progression reflected longitudinal changes in cognition, outcomes, and local brain changes, while BA captured treatment-related and global brain alterations. The SZ-HC model was also generalizable to independent schizophrenia validation samples but classified depression as control subjects. Our research underlines the importance of taking account of longitudinal progression in a disorder-specific pattern in schizophrenia when developing ML classifiers for different age groups.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00157-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39231793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal association between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies.","authors":"Emanuele F Osimo, Luke Baxter, Jan Stochl, Benjamin I Perry, Stephen A Metcalf, Setor K Kunutsor, Jari A Laukkanen, Marie Kim Wium-Andersen, Peter B Jones, Golam M Khandaker","doi":"10.1038/s41537-021-00161-4","DOIUrl":"10.1038/s41537-021-00161-4","url":null,"abstract":"<p><p>Meta-analyses of cross-sectional studies suggest that patients with psychosis have higher circulating levels of C-reactive protein (CRP) compared with healthy controls; however, cause and effect is unclear. We examined the prospective association between CRP levels and subsequent risk of developing a psychotic disorder by conducting a systematic review and meta-analysis of population-based cohort studies. Databases were searched for prospective studies of CRP and psychosis. We obtained unpublished results, including adjustment for age, sex, body mass index, smoking, alcohol use, and socioeconomic status and suspected infection (CRP > 10 mg/L). Based on random effect meta-analysis of 89,792 participants (494 incident cases of psychosis at follow-up), the pooled odds ratio (OR) for psychosis for participants with high (>3 mg/L), as compared to low (≤3 mg/L) CRP levels at baseline was 1.50 (95% confidence interval [CI], 1.09-2.07). Evidence for this association remained after adjusting for potential confounders (adjusted OR [aOR] = 1.31; 95% CI, 1.03-1.66). After excluding participants with suspected infection, the OR for psychosis was 1.36 (95% CI, 1.06-1.74), but the association attenuated after controlling for confounders (aOR = 1.23; 95% CI, 0.95-1.60). Using CRP as a continuous variable, the pooled OR for psychosis per standard deviation increase in log(CRP) was 1.11 (95% CI, 0.93-1.34), and this association further attenuated after controlling for confounders (aOR = 1.07; 95% CI, 0.90-1.27) and excluding participants with suspected infection (aOR = 1.07; 95% CI, 0.92-1.24). There was no association using CRP as a categorical variable (low, medium or high). While we provide some evidence of a longitudinal association between high CRP (>3 mg/L) and psychosis, larger studies are required to enable definitive conclusions.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10610235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome prediction with a social cognitive battery: a multicenter longitudinal study.","authors":"Eric Brunet-Gouet, Capucine Decaix-Tisserand, Mathieu Urbach, Nadine Bazin, Bruno Aouizerate, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Caroline Dubertret, Julien Dubreucq, Guillaume Fond, Christophe Lançon, Sylvain Leignier, Jasmina Mallet, David Misdrahi, Sylvie Pires, Priscille Schneider, Franck Schurhoff, Hanan Yazbek, Anna Zinetti-Bertschy, Christine Passerieux, Paul Roux","doi":"10.1038/s41537-021-00160-5","DOIUrl":"10.1038/s41537-021-00160-5","url":null,"abstract":"<p><p>The interest in social cognition in schizophrenia is justified by the relationship between deficits in these skills and negative functional outcomes. Although assessment batteries have already been described, there is no consensus about which measures are useful in predicting patient functioning or quality of life (QoL). We investigated a set of five measures of recognition of facial emotions, theory of mind (ToM), and empathy in a cohort of 143 patients with schizophrenia or schizoaffective disorder at inclusion and, amongst whom 79 were reassessed 1 year later. The distribution was satisfactory for the TREF (Facial Emotion Recognition Task), V-SIR (Versailles-Situational Intention Reading), and QCAE (Questionnaire of Cognitive and Affective Empathy). Internal consistency was satisfactory for the TREF, V-SIR, V-Comics (Versailles Intention Attribution Task), and QCAE. Sensitivity to change was acceptable for the TREF. The TREF and V-SIR showed a cross-sectional relationship with functioning beyond the clinical symptoms of schizophrenia but not beyond neurocognition. Moreover, the TREF and V-SIR at inclusion could not predict functioning one year later, whereas most neurocognitive and clinical dimensions at inclusion could. Finally, only affective QCAE showed a significant cross-sectional, but not longitudinal, association with QoL. In conclusion, the TREF had satisfactory psychometric properties and showed a cross-sectional, but not longitudinal, association with objective outcome measures, thus appearing to be reliable in clinical practice and research. The V-SIR also showed promising psychometric properties, despite a possible weakness to detect change. However, these measures should be interpreted within the context of the good predictive power of the neurocognitive and clinical status on the outcome.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":null,"pages":null},"PeriodicalIF":5.4,"publicationDate":"2021-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00160-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38952650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}